CDMRP: Neurofibromatosis Research Opportunities - LOI required

Sponsor Deadline: 

Jul 21, 2022

Letter of Intent Deadline: 

Jun 30, 2022

Sponsor: 

DOD Defense Congressionally Directed Medical Research Programs (CDMRP)

UI Contact: 

Sponsor link https://cdmrp.army.mil/funding/nfrp

Applications submitted to the FY22 NFRP must address one or more of the following Areas of Emphasis:

  • Neurofibromatosis (NF) Type 2-related areas (e.g., hearing, balance, ependymoma, meningioma)
  • Biomarker discovery, utility, development, and validation
  • Non-tumor manifestations not limited to:
    • Pain
    • Cognitive manifestations
    • Sleep
  • Heterogeneity of NF-related tumors
  • Novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
  • Preclinical efficacy studies
  • Target identification, drug discovery
  • Nutritional, environmental, and other modifiers of NF
  • Health services research

 

Funding Opportunities-FY21 NFRP, Congressionally Directed Medical Research Programs (CDMRP), US DoD (army.mil)

 

Clinical Trial Award – Letter of Intent due June 20, 2022

Must be at or above the level of Assistant Professor (or equivalent).

  • Supports research with the potential to have a major impact on the treatment or management of NF.
  • Funds phase 0, 1, or 2 clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted.
  • Must support a clinical trial and may not be used for preclinical research studies.
  • The maximum period of performance is 4 years.
  • The maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting the Qualified Organizational Collaboration Option).
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Exploration – Hypothesis Development Award – Letter of Intent due June 30, 2022

  • Supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in NF research.
  • Preliminary and/or published data are encouraged but not required.
  • Clinical trials are not allowed.
  • The maximum period of performance is 2 years.
  • The maximum allowable funding for the entire period of performance is $100,000 in direct costs.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Investigator-Initiated Research Award – Letter of Intent due June 30, 2022

Must be either:

  • Early-Stage Investigator (ESI) - An independent investigator at or below the level of Assistant Professor (or equivalent) who plans to commit at least 30% of their effort toward the proposed research project; or
  • Established Investigator (EI) - An independent investigator in an area other than neurofibromatosis (NF) at or above the level of Assistant Professor seeking to transition into a career in NF research who plans to commit at least 10% of their effort toward the proposed research project.

Applicants may not have received more than $300,000 in direct costs for NF research as a Principal Investigator of any program within CDMRP.

New Investigator Award – Letter of Intent due June 30, 2022

Early-Stage Investigator (ESI):  An independent investigator at or below the level of Assistant Professor (or equivalent) and commit at least 30% during each budget year of their efforts toward the proposed NF research project.

Established Investigator (EI): An independent investigator above the level of Assistant Professor and commit at least 10% during each budget year of their efforts toward the proposed NF research project.

  • ESI:  Supports the continued development of promising independent investigators
  • EI:  Supports the transition of established investigators from other research fields into a career in NF research.
  • Prior experience in NF research is not required.
  • Preliminary and/or published data relevant to NF and the proposed research project are required.
  • Clinical trials are not allowed.
  • The maximum period of performance is 3 years.
  • The maximum allowable funding for the entire period of performance is $450,000 in direct costs.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Early Investigator Research Award – Letter of Intent due June 30, 2022

The investigator must:

  • Be involved in a postdoctoral training or medical residency program;
  • Possess up to 4 years of continuous postdoctoral research experience by application submission deadline; and
  • Possess a doctoral degree (i.e., Ph.D., M.D./Ph.D., D.O./Ph.D.) or a clinical doctoral degree (i.e., M.D./D.O. or Ph.D. in a clinical discipline) from an accredited organization or program.  Must commit at least 50% of effort to the project.
  • Supports NF-focused research opportunities for individuals in the early stages of their careers.
  • Investigators must have a designated mentor who is an experienced NF researcher.
  • The maximum period of performance is 2 years.
  • The maximum allowable funding for the entire period of performance is $200,000 in direct costs.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Synergistic Idea Award

Must be an investigator at or above the level of Assistant Professor (or equivalent) who plans to commit at least a 10% level of effort for each budget period throughout the entirety of the award.

 

  • Supports new ideas that represent synergistic approaches involving two or three Principal Investigators (PIs) (Initiating PIs and PI[s]) to address a central problem or question in NF research.
  • Preliminary and/or published data are required.
  • Clinical trials are not allowed
  • The maximum period of performance is 3 years.
  • The maximum allowable funding for the entire period of performance is $2,000,000 in direct costs.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Categories: